<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02404480</url>
  </required_header>
  <id_info>
    <org_study_id>PTC596-ONC-001-AST</org_study_id>
    <nct_id>NCT02404480</nct_id>
  </id_info>
  <brief_title>PTC596 in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, first-in-human, safety and pharmacokinetic study of PTC596 in
      patients with advanced cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, open-label, first-in-human, safety and pharmacokinetic (PK) study of
      PTC596 in patients with advanced cancer. A variation of the traditional 3+3 dose escalation
      design will be employed.

      PTC596 will be administered orally on a twice a week (biw) schedule. Each 4-week period of
      drug administration will be considered one cycle. The objective of the study will be to
      determine the recommended Phase 2 dose (RP2D) and to determine preliminary proof of mechanism
      of action.

      Collectively, data from the Good Laboratory Practice (GLP) and non-GLP studies indicate that
      40 mg/kg biw is approximately the severely toxic dose in 10% of animals (STD 10). Therefore,
      the starting dose in this study will be calculated as one-tenth of the human equivalent dose
      (HED) of 40 mg/kg biw in rats, which is 0.65 mg/kg biw.

      In this study, escalating dose levels will be evaluated to determine the RP2D. Three patients
      will be enrolled at the starting dose level (0.65 mg/kg biw); if 1 of the 3 patients
      experiences a dose-limiting toxicity (DLT), an additional 3 patients will be enrolled at the
      same dose level. Thus, 3 to 6 patients will receive the starting dose level of 0.65 mg/kg.
      Dose escalation will continue until the occurrence of DLT in ≥2/6 patients at a given dose
      level. Dose escalation will occur in approximately 100% increments until Grade ≥2,
      first-cycle toxicity is seen in at least 2 patients across all dose levels, after which dose
      escalation will occur in smaller (50% or 33%) increments.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">February 6, 2017</completion_date>
  <primary_completion_date type="Actual">February 6, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, first-in-human, safety and pharmacokinetic (PK)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicities</measure>
    <time_frame>28 days</time_frame>
    <description>Determine the RP2D based on occurrence of DLTs and/or biological efficacy as determined by biomarker changes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>28days</time_frame>
    <description>Define and describe the adverse effects of PTC596 in humans when orally administered on a biw schedule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (T max)</measure>
    <time_frame>28days</time_frame>
    <description>Evaluate the Time to Maximum Plasma Concentration (T max) of PTC596 in humans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>28days</time_frame>
    <description>Describe any preliminary evidence of antitumor activity of PTC596.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (C max)</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluate the Maximum Plasma Concentration (C max) of PTC596 in humans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration at 24 hours</measure>
    <time_frame>28days</time_frame>
    <description>Evaluate the Plasma Concentration at 24 hours of PTC596 in humans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>28 days</time_frame>
    <description>Evaluate the area under the plasma concentration-time curve (AUC) of PTC 596 in humans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2).</measure>
    <time_frame>28 days.</time_frame>
    <description>Evaluate the terminal half-life (t1/2) of PTC 596 in humans.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC 596 administered twice daily- Dose level 0.65mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC 596 administered twice daily-Dose level 1.3mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC 596 administered twice daily-2.6mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC 596 administered twice daily-Dose level 5.2mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC 596 administered twice daily-Dose level 10mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC 596 administered twice daily-Dose level 7mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7 (Bio Marker cohort)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PTC 596 administered twice daily-Dose level 5.2mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PTC596</intervention_name>
    <description>PTC 596 will be administered orally twice a day until unmanageable toxicity, disease progression, or withdrawal of consent is noted</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7 (Bio Marker cohort)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed solid malignancy that is
             metastatic or unresectable, for which standard curative measures do not exist, that
             has progressed on at least one line of standard therapy or for which no standard
             therapies exists

          -  Discontinuation of all other therapies (including other investigational drugs,
             radiotherapy, or chemotherapy) for the treatment of cancer ≥4 weeks (≥6 weeks if
             nitrosoureas, ≥12 weeks if radiotherapy) before initiation of study treatment

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  Life expectancy of at least 3 months

          -  A measured or estimated creatinine clearance (CrCl) ≥60 mL/min/1.73 m2

        Exclusion Criteria:

          -  Prior bone marrow/hematopoietic stem cell transplantation

          -  History of solid organ, bone marrow, or progenitor cell transplantation

          -  History of major surgical procedure within 28 days prior to start of study treatment

          -  Evidence of ongoing systemic bacterial, fungal, or viral infection. Known human
             immunodeficiency virus (HIV) infection or acquired-immunodeficiency syndrome
             (AIDS)-related illness

          -  Any of the following in the past 6 months: myocardial infarction, unstable angina,
             coronary/peripheral artery bypass graft, congestive heart failure (New York Heart
             Association Class III or IV), cerebrovascular accident, transient ischemic attack,
             other arterial thromboembolic event, or pulmonary embolism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward O'Mara, MD</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4Y2H8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.brainlife.org/abstract/2009/Abdouh_M090715.pdf</url>
    <description>BMI1 sustains human glioblastoma multiformae stem cell renewal.</description>
  </link>
  <link>
    <url>http://www.nature.com/articles/6691791</url>
    <description>Characterization and Chromosomal localization of the human proto-oncogene</description>
  </link>
  <link>
    <url>http://www.nejm.org/doi/pdf/10.1056/NEJM200506093522319</url>
    <description>Phase 1 clinical trials in oncology</description>
  </link>
  <link>
    <url>http://www.mdpi.com/2072-6694/3/2/1777/htm</url>
    <description>Brain cancer stem cells</description>
  </link>
  <link>
    <url>http://cancerres.aacrjournals.org/content/69/4/1302.full</url>
    <description>Stem cell origin of death from cancer phenotypes of human prostate and breat cancer.</description>
  </link>
  <link>
    <url>http://www.proteinatlas.org/ENSG00000168283-BMI1/tissue</url>
    <description>Human protein atlas</description>
  </link>
  <link>
    <url>https://www.researchgate.net/publication/5465319_Exploratory_assessment_of_dose_proportionality_Review_of_current_approaches_and_proposal_for_a_practical_criterion</url>
    <description>Exploratory assessment of dose proportionality</description>
  </link>
  <link>
    <url>https://prsinfo.clinicaltrials.gov/trainTrainer/Dose-Escalation-Design-Fiction-Manuscript.pdf</url>
    <description>Dose escalation study design example</description>
  </link>
  <link>
    <url>https://rd.springer.com/article/10.1007/s00432-007-0316-8?no-access=true</url>
    <description>Increased polycomb-group oncogene BMI-1expression coorelates with poor prognosis in Hepatocellular carcinoma</description>
  </link>
  <reference>
    <citation>Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G. BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009 Jul 15;29(28):8884-96. doi: 10.1523/JNEUROSCI.0968-09.2009.</citation>
    <PMID>19605626</PMID>
  </reference>
  <reference>
    <citation>American Society of Clinical Oncology, Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006 Jun 20;24(18):2932-47. Epub 2006 May 22. Erratum in: J Clin Oncol. 2006 Nov 20;24(33):5341-2.</citation>
    <PMID>16717289</PMID>
  </reference>
  <reference>
    <citation>Beck B, Blanpain C. Unravelling cancer stem cell potential. Nat Rev Cancer. 2013 Oct;13(10):727-38. doi: 10.1038/nrc3597. Review.</citation>
    <PMID>24060864</PMID>
  </reference>
  <reference>
    <citation>Cao R, Tsukada Y, Zhang Y. Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. Mol Cell. 2005 Dec 22;20(6):845-54.</citation>
    <PMID>16359901</PMID>
  </reference>
  <reference>
    <citation>Chiba T, Miyagi S, Saraya A, Aoki R, Seki A, Morita Y, Yonemitsu Y, Yokosuka O, Taniguchi H, Nakauchi H, Iwama A. The polycomb gene product BMI1 contributes to the maintenance of tumor-initiating side population cells in hepatocellular carcinoma. Cancer Res. 2008 Oct 1;68(19):7742-9. doi: 10.1158/0008-5472.CAN-07-5882.</citation>
    <PMID>18829528</PMID>
  </reference>
  <reference>
    <citation>Cho JH, Dimri M, Dimri GP. A positive feedback loop regulates the expression of polycomb group protein BMI1 via WNT signaling pathway. J Biol Chem. 2013 Feb 1;288(5):3406-18. doi: 10.1074/jbc.M112.422931. Epub 2012 Dec 13.</citation>
    <PMID>23239878</PMID>
  </reference>
  <reference>
    <citation>Costa DB, Li S, Kocher O, Feins RH, Keller SM, Schiller JH, Johnson DH, Tenen DG, Halmos B. Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590. Lung Cancer. 2007 Apr;56(1):97-103. Epub 2007 Jan 18.</citation>
    <PMID>17239984</PMID>
  </reference>
  <reference>
    <citation>Douglas D, Hsu JH, Hung L, Cooper A, Abdueva D, van Doorninck J, Peng G, Shimada H, Triche TJ, Lawlor ER. BMI-1 promotes ewing sarcoma tumorigenicity independent of CDKN2A repression. Cancer Res. 2008 Aug 15;68(16):6507-15. doi: 10.1158/0008-5472.CAN-07-6152.</citation>
    <PMID>18701473</PMID>
  </reference>
  <reference>
    <citation>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.</citation>
    <PMID>19097774</PMID>
  </reference>
  <reference>
    <citation>Facchino S, Abdouh M, Chatoo W, Bernier G. BMI1 confers radioresistance to normal and cancerous neural stem cells through recruitment of the DNA damage response machinery. J Neurosci. 2010 Jul 28;30(30):10096-111. doi: 10.1523/JNEUROSCI.1634-10.2010.</citation>
    <PMID>20668194</PMID>
  </reference>
  <reference>
    <citation>Fan C, He L, Kapoor A, Rybak AP, De Melo J, Cutz JC, Tang D. PTEN inhibits BMI1 function independently of its phosphatase activity. Mol Cancer. 2009 Nov 10;8:98. doi: 10.1186/1476-4598-8-98.</citation>
    <PMID>19903340</PMID>
  </reference>
  <reference>
    <citation>Glinsky GV, Berezovska O, Glinskii AB. Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005 Jun;115(6):1503-21.</citation>
    <PMID>15931389</PMID>
  </reference>
  <reference>
    <citation>Guney I, Wu S, Sedivy JM. Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16(INK4a). Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3645-50. Epub 2006 Feb 28.</citation>
    <PMID>16537449</PMID>
  </reference>
  <reference>
    <citation>Kreso A, van Galen P, Pedley NM, Lima-Fernandes E, Frelin C, Davis T, Cao L, Baiazitov R, Du W, Sydorenko N, Moon YC, Gibson L, Wang Y, Leung C, Iscove NN, Arrowsmith CH, Szentgyorgyi E, Gallinger S, Dick JE, O'Brien CA. Self-renewal as a therapeutic target in human colorectal cancer. Nat Med. 2014 Jan;20(1):29-36. doi: 10.1038/nm.3418. Epub 2013 Dec 1.</citation>
    <PMID>24292392</PMID>
  </reference>
  <reference>
    <citation>Li DW, Tang HM, Fan JW, Yan DW, Zhou CZ, Li SX, Wang XL, Peng ZH. Expression level of Bmi-1 oncoprotein is associated with progression and prognosis in colon cancer. J Cancer Res Clin Oncol. 2010 Jul;136(7):997-1006. doi: 10.1007/s00432-009-0745-7. Epub 2009 Dec 19.</citation>
    <PMID>20024662</PMID>
  </reference>
  <reference>
    <citation>Liu L, Andrews LG, Tollefsbol TO. Loss of the human polycomb group protein BMI1 promotes cancer-specific cell death. Oncogene. 2006 Jul 20;25(31):4370-5. Epub 2006 Feb 27.</citation>
    <PMID>16501599</PMID>
  </reference>
  <reference>
    <citation>Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ. Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature. 2003 Oct 30;425(6961):962-7. Epub 2003 Oct 22.</citation>
    <PMID>14574365</PMID>
  </reference>
  <reference>
    <citation>Nacerddine K, Beaudry JB, Ginjala V, Westerman B, Mattiroli F, Song JY, van der Poel H, Ponz OB, Pritchard C, Cornelissen-Steijger P, Zevenhoven J, Tanger E, Sixma TK, Ganesan S, van Lohuizen M. Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest. 2012 May;122(5):1920-32. doi: 10.1172/JCI57477. Epub 2012 Apr 16.</citation>
    <PMID>22505453</PMID>
  </reference>
  <reference>
    <citation>Nachimuthu S, Assar MD, Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf. 2012 Oct;3(5):241-53. doi: 10.1177/2042098612454283. Review.</citation>
    <PMID>25083239</PMID>
  </reference>
  <reference>
    <citation>Nakamura S, Oshima M, Yuan J, Saraya A, Miyagi S, Konuma T, Yamazaki S, Osawa M, Nakauchi H, Koseki H, Iwama A. Bmi1 confers resistance to oxidative stress on hematopoietic stem cells. PLoS One. 2012;7(5):e36209. doi: 10.1371/journal.pone.0036209. Epub 2012 May 11.</citation>
    <PMID>22606246</PMID>
  </reference>
  <reference>
    <citation>O'Connor ML, Xiang D, Shigdar S, Macdonald J, Li Y, Wang T, Pu C, Wang Z, Qiao L, Duan W. Cancer stem cells: A contentious hypothesis now moving forward. Cancer Lett. 2014 Mar 28;344(2):180-7. doi: 10.1016/j.canlet.2013.11.012. Epub 2013 Dec 11. Review.</citation>
    <PMID>24333726</PMID>
  </reference>
  <reference>
    <citation>Pan MR, Peng G, Hung WC, Lin SY. Monoubiquitination of H2AX protein regulates DNA damage response signaling. J Biol Chem. 2011 Aug 12;286(32):28599-607. doi: 10.1074/jbc.M111.256297. Epub 2011 Jun 15.</citation>
    <PMID>21676867</PMID>
  </reference>
  <reference>
    <citation>Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL, Morrison SJ, Clarke MF. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003 May 15;423(6937):302-5. Epub 2003 Apr 20.</citation>
    <PMID>12714971</PMID>
  </reference>
  <reference>
    <citation>Park IK, Morrison SJ, Clarke MF. Bmi1, stem cells, and senescence regulation. J Clin Invest. 2004 Jan;113(2):175-9. Review.</citation>
    <PMID>14722607</PMID>
  </reference>
  <reference>
    <citation>Siddique HR, Parray A, Tarapore RS, Wang L, Mukhtar H, Karnes RJ, Deng Y, Konety BR, Saleem M. BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling. PLoS One. 2013 May 6;8(5):e60664. doi: 10.1371/journal.pone.0060664. Print 2013.</citation>
    <PMID>23671559</PMID>
  </reference>
  <reference>
    <citation>Silva J, García JM, Peña C, García V, Domínguez G, Suárez D, Camacho FI, Espinosa R, Provencio M, España P, Bonilla F. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas. Clin Cancer Res. 2006 Dec 1;12(23):6929-36.</citation>
    <PMID>17145810</PMID>
  </reference>
  <reference>
    <citation>Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006 Nov;6(11):846-56. Review.</citation>
    <PMID>17060944</PMID>
  </reference>
  <reference>
    <citation>Vrzalikova K, Skarda J, Ehrmann J, Murray PG, Fridman E, Kopolovic J, Knizetova P, Hajduch M, Klein J, Kolek V, Radova L, Kolar Z. Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study. J Cancer Res Clin Oncol. 2008 Sep;134(9):1037-42. doi: 10.1007/s00432-008-0361-y. Epub 2008 Feb 9.</citation>
    <PMID>18264721</PMID>
  </reference>
  <reference>
    <citation>Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10;28(11):1963-72. doi: 10.1200/JCO.2009.26.3541. Epub 2010 Mar 15.</citation>
    <PMID>20231676</PMID>
  </reference>
  <reference>
    <citation>Wu Z, Min L, Chen D, Hao D, Duan Y, Qiu G, Wang Y. Overexpression of BMI-1 promotes cell growth and resistance to cisplatin treatment in osteosarcoma. PLoS One. 2011 Feb 2;6(2):e14648. doi: 10.1371/journal.pone.0014648.</citation>
    <PMID>21311599</PMID>
  </reference>
  <reference>
    <citation>Wu X, Liu X, Sengupta J, Bu Y, Yi F, Wang C, Shi Y, Zhu Y, Jiao Q, Song F. Silencing of Bmi-1 gene by RNA interference enhances sensitivity to doxorubicin in breast cancer cells. Indian J Exp Biol. 2011 Feb;49(2):105-12.</citation>
    <PMID>21428211</PMID>
  </reference>
  <reference>
    <citation>Zhang P, Iwasaki-Arai J, Iwasaki H, Fenyus ML, Dayaram T, Owens BM, Shigematsu H, Levantini E, Huettner CS, Lekstrom-Himes JA, Akashi K, Tenen DG. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha. Immunity. 2004 Dec;21(6):853-63.</citation>
    <PMID>15589173</PMID>
  </reference>
  <reference>
    <citation>Zhang R, Xu LB, Yue XJ, Yu XH, Wang J, Liu C. Bmi1 gene silencing inhibits the proliferation and invasiveness of human hepatocellular carcinoma cells and increases their sensitivity to 5-fluorouracil. Oncol Rep. 2013 Mar;29(3):967-74. doi: 10.3892/or.2012.2189. Epub 2012 Dec 14.</citation>
    <PMID>23242307</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2015</study_first_submitted>
  <study_first_submitted_qc>March 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2015</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

